ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

被引:41
作者
Borroni, B
Colciaghi, F
Pastorino, L
Archetti, S
Corsini, P
Cattabeni, F
Di Luca, M
Padovani, A
机构
[1] Univ Brescia, Dept Neurol, I-25123 Brescia, Italy
[2] Univ Brescia, Dept Biotechnol, I-25121 Brescia, Italy
[3] Univ Milan, Inst Pharmaceut Sci, I-20122 Milan, Italy
关键词
Alzheimer disease; amyloid precursor protein (APP); donepezil; apolipoprotein E;
D O I
10.1016/S0924-977X(02)00013-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Three major amyloid precursor protein (APP) forms with apparent molecular A eight ranging from 106 to 130 kDa are present in human platelets. Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. A total of 25 mild to moderate AD patients were investigated. Platelet APPr was studied before and after 30 days of acetylcholinesterase-inhibitor ;treatment (donepezil, 5 mg daily). Patients were grouped into non-is an element of4 carriers and is an element of4 carriers according to apolipoprotein E (ApOE) genotype. At baseline. all patients showed low APPr levels and no significant difference was found between the two ApoE subgroups. After treatment. although a marked improvement in APPr was observed in most patients. non-is an element of4 carriers displayed a higher increase compared to is an element of4 carriers (P<0.0001). The present study provides evidence that donepezil influences APP metabolism in platelets, and suggests that ApoE genotype might be an important modulating factor for drug responsiveness in AD. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 44 条
[1]
APOE genotype:: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease [J].
Aerssens, J ;
Raeymaekers, P ;
Lilienfeld, S ;
Geerts, H ;
Konings, F ;
Parys, W .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (02) :69-77
[2]
Platelet APP isoform ratios correlate with declining cognition in AD [J].
Baskin, F ;
Rosenberg, RN ;
Iyer, L ;
Hynan, L ;
Cullum, CM .
NEUROLOGY, 2000, 54 (10) :1907-1909
[3]
NONNEURAL MARKERS IN ALZHEIMER-DISEASE [J].
BLASS, JP ;
GIBSON, GE .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1992, 6 (04) :205-224
[4]
Bodovitz S, 1996, J BIOL CHEM, V271, P4436
[5]
Amyloid precursor protein in platelets of patients with Alzheimer disease -: Effect of acetylcholinesterase inhibitor treatment [J].
Borroni, B ;
Colciaghi, F ;
Pastorino, L ;
Pettenati, C ;
Cottini, E ;
Rozzini, L ;
Monastero, R ;
Lenzi, GL ;
Cattabeni, F ;
Di Luca, M ;
Padovani, A .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :442-446
[6]
Alzheimer disease-related abnormalities of amyloid β precursor protein isoforms in the platelet -: The brain's delegate in the periphery? [J].
Bush, AI ;
Tanzi, RE .
ARCHIVES OF NEUROLOGY, 1998, 55 (09) :1179-1180
[7]
PLATELETS ARE THE PRIMARY SOURCE OF AMYLOID BETA-PEPTIDE IN HUMAN BLOOD [J].
CHEN, M ;
INESTROSA, NC ;
ROSS, GS ;
FERNANDEZ, HL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 213 (01) :96-103
[8]
FLOW CYTOMETRIC MEASUREMENTS OF CYTOPLASMIC CALCIUM CHANGES IN HUMAN-PLATELETS [J].
DAVIES, TA ;
DROTTS, D ;
WEIL, GJ ;
SIMONS, ER .
CYTOMETRY, 1988, 9 (02) :138-142
[9]
Moderate and advanced Alzheimer's patients exhibit platelet activation differences [J].
Davies, TA ;
Long, HJ ;
Tibbles, HE ;
Sgro, KR ;
Wells, JM ;
Rathbun, WH ;
Seetoo, KF ;
McMenamin, ME ;
Smith, SJ ;
Feldman, RG ;
Levesque, CA ;
Fine, RE ;
Simons, ER .
NEUROBIOLOGY OF AGING, 1997, 18 (02) :155-162
[10]
Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein [J].
Di Luca, M ;
Colciaghi, F ;
Pastorino, L ;
Borroni, B ;
Padovani, A ;
Cattabeni, F .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 405 (1-3) :277-283